 |
 |
 |
 |
 |
 |
||
 |
||
 |
||
 |
||
 |
||
 |
||
 |
||
| News 2013 | |
| October 2013 | 8th Hanseatic India Colloqium The 8th Hanseatic India Colloqium was an interesting, informative and very well attended meeting. We had several top Indian Pharmaceutical and biotech companies attending the event and we learnt about the excellent research and development work going on in India especially in the area of cost effective generics production. At the same time, several Hamburg based pharma and biotech companies presented data on how they have progressed in research and development work and outlined some of the avenues for effective Indo-German collaboration especially to develop innovative therapy at an affordable cost. |
| Program/Presentations | |
| Opening Session | |
| Word of Greetings by Stephan Matz, Director International Department, HWF Hamburg Business Development Corporation, Hamburg, Germany | |
| Welcome Address by Dr. Hinrich Habeck, Managing Director, Norgenta North German Life Science Agency, Hamburg, Germany | |
| Opening Address by H. E. Dr. Vidhu P. Nair, Acting Consul General of India, Hamburg, Germany | |
| Session I Chair: Dr. Amal Mukhopadhyay, Founder and Director, ELGA Biotech, Hamburg, Germany |
|
| Feeding the drug
discovery pipeline with innovative ideas from academia: A model
for Indo-German Collaboration
in R & D Dr. Björn Windshügel, Head of Bioinformatics, European Screening Port GmbH, Hamburg, Germany |
|
| Generics in healthcare in a global perspective:
Opportunities offered by India Vimalendu K. Singh, Chief Executive Global Generics, RPG Life Sciences Ltd., Mumbai, India |
|
| Clinical Research: A fundamental component
of drug discovery Prof. Dr. Rainer Böger, Managing Director, Clinical Trial Center North, Hamburg, Germany |
|
| Session II Chair: Dr. Hinrich Habeck, Managing Director, Norgenta North German Life Science Agency, Hamburg, Germany |
|
| Generic drug development, Indian scenario Dr. Vijay K. Shastri, Technical Director, Murli Krishna Pharma Pvt. Ltd, Pune, India |
|
| API manufacturing in India: Opportunities
and challenges especially with the issue of quality control Dr. Antony Raj Gomas, Sr. Vice President – Quality, Mylan Laboratories Ltd., Hyderabad, India |
|
| Legal challenges for transnational co-operations
in drug development and clinical research Dr. Stefanie Greifeneder, Partner Munich, Field Fisher Waterhouse LLP, Munich, Germany |
|
| Session III Chair: Dr. Antony Raj Gomas, Sr. Vice President – Quality, Mylan Laboratories Ltd., Hyderabad, India |
|
| 50 Years of Generic Experience - Exploiting
Synergies in India Dr. Harm Peters, Managing Director, AET Biotechnologie GmbH, Hamburg, Germany |
|
| Scaling Business to the next level, Pharmaceutical
Industry Satya R. Vadlamani, Chief Managing Director, Murli Krishna Pharma Pvt. Ltd, Pune, India |
|
| Richter-Helm: Global Partner for Biotechnology
and Biosimilars Federico Pollano, Managing Director, Richter-Helm Biotec GmbH & Co KG, Hamburg, Germany |
|
| Adding a New Dimension: Extending Business
from Small Molecules To Biologics Dr. Wolfram Altenhofen, Vice President Business Development, AET Biotechnologie GmbH, Hamburg, Germany |
|
| Conclusion of the Event and Networking | |
© 2007-2020
ELGA BIOTECH |
 |